Simulator calibrated on STEP-2. Project weight loss, body composition, and muscle loss risk on Semaglutide 1.0 mg, fitted to your own body.
In the STEP-2 trial, Semaglutide 1.0 mg produced -9.6% over 68 weeks. But a trial average is not your result: response varies with sex, age, starting BMI, dose reached, and what you do about protein and training. Use the simulator to see the curve applied to your own body.
Loss is not linear. It is slow in the first weeks because of dose titration, accelerates between month two and month five, then flattens toward a plateau. The simulator shows the estimated week your plateau starts.
Yes, some of the weight lost is lean mass in any rapid weight loss. Without high protein and resistance training, roughly 30% of what you lose tends to be muscle. With both, that drops to around 13%. The simulator runs both scenarios on your data.
Withdrawal data shows roughly two thirds of the lost weight returns within 12 months without a maintenance protocol. With structured maintenance, the literature points to around one fifth. The post-treatment tab shows both curves.
Current status: FDA approved. This tool calculates based on what you report using and does not advise starting, stopping, or dosing. That is a conversation with your doctor.